



Global Legal Chronicle: Akeso Biopharma's US\$333 Million Hong Kong IPO

April 28, 2020

RELATED PROFESSIONALS

Ke Geng

Beijing
D: +86-10-6563-4261

Ke Zhu

Hong Kong
D: +852-3512-2333

Yiming Liu

Shanghai
D: +86-21-2307-7077

Qianyu Hu

Hong Kong
D: +852-3512-2361

Grace Xu

Hong Kong
D: +852-3512-4057

Yiyang Wang

Shanghai
D: +86-21-2307-7065

Henry Wong

Hong Kong
D: +852-3512-4032

Sydney Ryan

San Francisco
D: +1-415-984-8908

Edward Poon

Hong Kong
D: +852-3512-2350

O'Melveny advised Akeso Biopharma (Akeso) in its IPO and listing on the Hong Kong Stock Exchange, this article reported. The IPO offering size is HK\$2.58 billion (US\$330 million), making it 2020's largest Hong Kong IPO to date, *Global Legal Chronicle* reported. Akeso is a leading Chinese clinical-stage biotech company specializing in oncology and immunology.

The O'Melveny team that advised Akeso included partners Ke Geng and Ke Zhu, counsel Yiming Liu and Qianyu Hu, and associates Grace Xu, Yiyang Wang, Henry Wong, Sydney Ryan, and Edward Poon, and trainee solicitors Hilda Leung and Dave Chan.

Read the full article [here](#).

RELATED PRACTICES

Capital Markets